In this video, Amrita Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope Cancer Center, discusses major developments in multiple myeloma presented at ASCO Annual Meeting.
Krishnan highlights new data on T-cell redirecting therapies, including teclistamab therapies showing high response rates and durable responses, as well as new data showing high response rates on other bispecifics.
Krishnan also discussed the major challenges and unanswered questions moving forward, and directions for future scholarship.
